Nephrology

There was no difference in the incidence of BKPyV, CMV, or EBV in patients who received HCV NAT-positive donor kidneys versus those who received HCV NAT-negative donor kidneys.

Barratt reflects on recent therapeutic developments in IgAN, the most recent being the full FDA approval of sparsentan (Filspari), and the importance of preventing kidney failure.

The FDA has granted full approval to sparsentan (Filspari) for slowing kidney function decline in adults with IgAN at risk of disease progression based on PROTECT trial data.

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

The August 2024 month in review highlights our coverage of pipeline news, a cross-specialty feature about dialysis, and other recent renal news and research from the past few weeks.

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.

Findings from a recent national registry study suggest perioperative mortality after living kidney donation significantly declined in 2013-2022 compared with 1993-2002 and 2003-2012.

The majority of highly suspected COVID-19 vaccine-associated glomerular disease cases were diagnosed as immunoglobulin A nephropathy and eventually improved with treatment.

Results suggest the potential utility of several nutritional indexes for reflecting IgAN severity and predicting end-stage renal disease risk.

Findings link greater thiazide doses to increased reductions in urine calcium and fewer subsequent symptomatic kidney stone events.

A new study reveals dialysis increases life expectancy but reduces time at home for older adults below the eGFR threshold of 12 mL/min/1.73 m².

Care for dialysis patients often focuses on kidney health, but experts and a patient stress the need for interdisciplinary care that also addresses sleep health.

Findings from the bidirectional 2-sample Mendelian randomization study suggest a strong positive causal association between atopic dermatitis and IgAN.

Findings suggest increased intensity of IgM deposits in patients with positive IgM deposition may contribute to adverse clinicopathologic presentation and clinical outcomes.

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Findings from a prespecified secondary analysis of the reduced-dose cohort of the TESTING trial suggest the efficacy of a lower dose of oral methylprednisolone in IgA nephropathy.

Positive topline results from the phase 3 VALIANT study show promise for pegcetacoplan in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

On August 07, 2024, Novartis announced the FDA's accelerated approval of iptacopan for reducing proteinuria in primary IgAN based on interim data from APPLAUSE-IgAN.

Study findings suggest the need for individualized management of patients with IgAN following COVID-19 infection based on baseline renal function status.

Findings support the use of mineralocorticoid receptor antagonists for the short-term reduction of proteinuria in patients with IgAN.

This July 2024 month in review highlights renal pipeline updates, new patient-focused CKD guidelines, and other top nephrology news and research.